Latest Factor VII Stories
WARSAW, Poland and NES-ZIONA, Israel, Feb. 6, 2013 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present new data on its long-acting clotting factor VIIa (Factor Vlla-CTP) at the Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD). PROLOR's Factor VIIa-CTP is a next-generation investigational therapy currently in advanced preclinical development for the potential treatment of patients with...
KING OF PRUSSIA, Pa., Jan. 21, 2013 /PRNewswire/ -- CSL Behring has announced that the first patient has been enrolled in the pivotal pediatric phase III study to evaluate the safety, efficacy and pharmacokinetics of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP) in previously treated children (up to age 11 years). The study site for this first enrollment is the Czech Republic. "CSL continues to advance at a very encouraging rate with...
WAYNE, N.J., Nov. 28, 2012 /PRNewswire/ -- Bayer's BAY 86-6150 is being investigated in a Phase II/III study called TRUST (TReatment with Unique recombinant rFVIIa STudy), and the recruitment of the first cohort is now complete. Recruitment is ongoing at sites located around the world, including in the U.S., where sites are ready to enroll eligible patients. The TRUST trial is designed to evaluate the safety and efficacy of the investigational compound BAY 86-6150, a...
CAMBRIDGE, Mass., Sept. 13, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc., an emerging biopharmaceutical company developing new treatment options for people with hemophilia, today announced that John P. Butler, Chief Executive Officer, will present at the UBS Global Life Sciences Conference on Thursday, September 20, 2012. The presentation will take place at 4:00 p.m. ET at the Grand Hyatt Hotel in New York. About Inspiration BiopharmaceuticalsAs the only...
LONDON and MOSCOW, September 11, 2012 /PRNewswire/ -- Subcutaneous blood factors expected to revolutionise the treatment paradigm of haemophiliac patients worldwide Pro Bono Bio Group plc ("PBB"), the international healthcare group, announces the successful conclusion of a series of pre-clinical trials in haemophiliac subjects conducted with the world's first long acting blood Factors VIIa, VIII and IX capable of subcutaneous...
CAMBRIDGE, Mass., Aug. 21, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals Inc. (Inspiration) today announced new license, development and commercialization agreements with its strategic partner, Ipsen (Euronext: IPN, ADR: IPSEY). The agreements restructure the existing partnership with Ipsen and provide Inspiration with additional funding to support development of its two investigational drugs in late-stage development for hemophilia, IB1001 and OBI-1. Under the terms of...
CAMBRIDGE, Mass., Aug. 2, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) announced today that it has added new leaders who will play pivotal roles as the company moves toward commercialization of products in late-stage development for hemophilia. Inspiration has appointed Robert Corcoran as Senior Vice President, Quality, Mike Keavany as Vice President of Commercial Operations, North America, Mark De Rosch, Ph.D., as Vice President, Regulatory Affairs, Neil...
WAYNE, N.J., July 10, 2012 /PRNewswire/ -- Bayer HealthCare today announced the 2012 recipients of the Bayer Hemophilia Awards Program (BHAP). This year, the company awards a total of approximately $2.3 million USD in funding to 15 recipients in nine countries. BHAP is the largest program of its kind in hemophilia, funding innovative research and educational initiatives around the world. As such, BHAP is part of Bayer's commitment to research, support and disease management in...
CAMBRIDGE, Mass., July 10, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that the agency has placed a clinical hold on clinical trials evaluating the safety and efficacy of IB1001, an intravenous recombinant factor IX (rFIX) being investigated for the treatment and prevention of bleeding episodes in people with hemophilia B. The clinical hold impacts two ongoing...
PARIS, July 9, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today reported data from its ongoing Phase 2/3 study evaluating the efficacy of OBI-1, an investigational recombinant porcine factor VIII (FVIII), for the treatment of serious bleeds in people with acquired hemophilia A. According to the interim analysis, seven out of seven trial participants receiving OBI-1 experienced control and subsequent resolution of their bleeds. Edward Gomperts, MD,...
